CIRC (01763) Subsidiary Atom High-Tech Signs Commercial Cooperation Agreement with Novartis AG

Stock News12-15 21:18

CIRC (01763) announced that its subsidiary, Atom High-Tech Co., Ltd., has officially signed a commercial cooperation agreement with Novartis Pharma Tech (Zhejiang) Co., Ltd. (Novartis AG) for Pluvicto® (lutetium [177Lu] vipivotide tetraxetan injection).

Pluvicto® is the first and currently the only approved PSMA-targeted radioligand therapy in China, primarily used for treating advanced prostate cancer. It offers a novel nuclear medicine treatment option aimed at prolonging patients' lives and improving their quality of life.

This agreement marks the beginning of a strategic collaboration between the two companies in the innovative nuclear medicine product Pluvicto®. Leveraging its years of compliant operational experience in the radiopharmaceutical sector, Atom High-Tech will join forces with Novartis AG to provide customized Pluvicto® product supply and solutions for medical institutions and patients, benefiting a broader patient population.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133966357?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 21:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133966357","market":"fut","top_or_hot":-1,"title":"CIRC (01763) Subsidiary Atom High-Tech Signs Commercial Cooperation Agreement with Novartis AG","media":"Stock News","content":"<p>CIRC (01763) announced that its subsidiary, Atom High-Tech Co., Ltd., has officially signed a commercial cooperation agreement with Novartis Pharma Tech (Zhejiang) Co., Ltd. (Novartis AG) for Pluvicto® (lutetium [177Lu] vipivotide tetraxetan injection).</p>\n<p>Pluvicto® is the first and currently the only approved PSMA-targeted radioligand therapy in China, primarily used for treating advanced prostate cancer. It offers a novel nuclear medicine treatment option aimed at prolonging patients' lives and improving their quality of life.</p>\n<p>This agreement marks the beginning of a strategic collaboration between the two companies in the innovative nuclear medicine product Pluvicto®. Leveraging its years of compliant operational experience in the radiopharmaceutical sector, Atom High-Tech will join forces with Novartis AG to provide customized Pluvicto® product supply and solutions for medical institutions and patients, benefiting a broader patient population.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CIRC (01763) Subsidiary Atom High-Tech Signs Commercial Cooperation Agreement with Novartis AG</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCIRC (01763) Subsidiary Atom High-Tech Signs Commercial Cooperation Agreement with Novartis AG\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-15 21:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CIRC (01763) announced that its subsidiary, Atom High-Tech Co., Ltd., has officially signed a commercial cooperation agreement with Novartis Pharma Tech (Zhejiang) Co., Ltd. (Novartis AG) for Pluvicto® (lutetium [177Lu] vipivotide tetraxetan injection).</p>\n<p>Pluvicto® is the first and currently the only approved PSMA-targeted radioligand therapy in China, primarily used for treating advanced prostate cancer. It offers a novel nuclear medicine treatment option aimed at prolonging patients' lives and improving their quality of life.</p>\n<p>This agreement marks the beginning of a strategic collaboration between the two companies in the innovative nuclear medicine product Pluvicto®. Leveraging its years of compliant operational experience in the radiopharmaceutical sector, Atom High-Tech will join forces with Novartis AG to provide customized Pluvicto® product supply and solutions for medical institutions and patients, benefiting a broader patient population.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002141913.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","start_time":0,"source_url":"","article_id":"1133966357","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133966357","pubTimestamp":1765804695,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CIRC (01763) announced that its subsidiary, Atom High-Tech Co., Ltd., has officially signed a commercial cooperation agreement with Novartis Pharma Tech (Zhejiang) Co., Ltd. (Novartis AG) for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4007":"制药","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK1222":"医疗保健用品","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4532":"文艺复兴科技持仓","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","NVS":"诺华","BK4585":"ETF&股票定投概念","BK4578":"CAR-T","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4588":"碎股","01763":"中国同辐"},"translate_title":"保监会(01763)附属凌动高新与诺华签署商业合作协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01763":1,"NVS":1},"content_text":"CIRC (01763) announced that its subsidiary, Atom High-Tech Co., Ltd., has officially signed a commercial cooperation agreement with Novartis Pharma Tech (Zhejiang) Co., Ltd. (Novartis AG) for Pluvicto® (lutetium [177Lu] vipivotide tetraxetan injection).\nPluvicto® is the first and currently the only approved PSMA-targeted radioligand therapy in China, primarily used for treating advanced prostate cancer. It offers a novel nuclear medicine treatment option aimed at prolonging patients' lives and improving their quality of life.\nThis agreement marks the beginning of a strategic collaboration between the two companies in the innovative nuclear medicine product Pluvicto®. Leveraging its years of compliant operational experience in the radiopharmaceutical sector, Atom High-Tech will join forces with Novartis AG to provide customized Pluvicto® product supply and solutions for medical institutions and patients, benefiting a broader patient population.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133966357","isCrawlerRequest":true}